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a b s t r a c t
Vascular smooth muscle cells (VSMCs) develop a highly proliferative and synthetic phenotype in arterial
diseases. Because such phenotypic changes are likely integrated with the energetic state of the cell, we
hypothesized that changes in cellular metabolism regulate VSMC plasticity. VSMCs were exposed to
platelet-derived growth factor-BB (PDGF) and changes in mitochondrial morphology, proliferation,
contractile protein expression, and mitochondrial metabolism were examined. Exposure of VSMCs to
PDGF resulted in mitochondrial fragmentation and a 50% decrease in the abundance of mitofusin 2.
Synthetic VSMCs demonstrated a 20% decrease in glucose oxidation, which was accompanied by an
increase in fatty acid oxidation. Results of mitochondrial function assays in permeabilized cells showed
few changes due to PDGF treatment in mitochondrial respiratory chain capacity and coupling. Treatment
of VSMCs with Mdivi-1—an inhibitor of mitochondrial ﬁssion—inhibited PDGF-induced mitochondrial
fragmentation by 50% and abolished increases in cell proliferation; however, it failed to prevent PDGF-
mediated activation of autophagy and removal of contractile proteins. In addition, treatment with Mdivi-
1 reversed changes in fatty acid and glucose oxidation associated with the synthetic phenotype. These
results suggest that changes in mitochondrial morphology and bioenergetics underlie the hyperproli-
ferative features of the synthetic VSMC phenotype, but do not affect the degradation of contractile
proteins. Mitochondrial fragmentation occurring during the transition to the synthetic phenotype could
be a therapeutic target for hyperproliferative vascular disorders.
& 2013 The Authors. Published by Elsevier B.V.
Introduction
Vascular smooth muscle cells (VSMCs) are essential in regulat-
ing vessel tone and blood ﬂow [1]. In vascular diseases such as
atherosclerosis or after percutaneous coronary interventions,
VSMCs lose their contractile function and convert to a highly
proliferative phenotype capable of producing elevated levels of
extracellular matrix. This VSMC phenotype, typically described as
the synthetic phenotype, can dramatically affect the composition
and stability of vascular lesions, or, in the case of restenosis,
promote vessel occlusion [2–7]. While several factors are involved
in mediating this phenotype transition, platelet-derived growth
factor-BB (PDGF) appears to be one of the most robust phenotype-
modulating agents. Its importance in vascular disease is adduced
by multiple studies showing that inhibition of either PDGF binding
to its cognate receptor or its downstream signaling inhibits smooth
muscle accumulation in the intima after arterial injury [8–15].
Furthermore, VSMCs lacking PDGFR-β demonstrate a resistance to
neointimal accumulation after carotid artery injury [16]. Therefore,
understanding how PDGF regulates the transition to the synthetic
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phenotype may be essential for developing strategies for preventing
or ameliorating diseases characterized by VSMC hyperproliferation.
Increasingly, mitochondrial metabolism is being recognized as a
critical regulator of cell growth and proliferation. Rapidly dividing
cells demonstrate enhanced glycolysis and glutamine utilization,
which helps provide energy, reducing equivalents, and the carbon
and nitrogen building blocks required for synthesis of daughter cells
[17]. In VSMCs, growth factors such as PDGF have been shown to
increase glycolysis and mitochondrial activity [18]. Recently, it was
also shown that, in the context of pulmonary artery hypertension,
VSMCs have higher rates of glycolysis [19] and develop a fragmen-
ted morphology [19,20]. Such changes in mitochondrial shape have
been shown to impact cell differentiation and proliferation directly
[21]; however, little is known regarding how mitochondrial struc-
ture regulates the phenotype and metabolic characteristics of
VSMCs. The goal of this study was to determine how PDGF affects
mitochondrial shape and metabolism in VSMCs and identify
whether such changes regulate the contractile-to-synthetic pheno-
type transition. We ﬁnd that PDGF-induced conversion to the
synthetic phenotype is accompanied by mitochondrial fragmenta-
tion, which regulates glucose and fat oxidation. This increase in the
fragmented mitochondrial phenotype was found to be critical to the
hyperproliferative response induced by PDGF.
Materials and methods
Reagents
Antibodies against ATP5A1, ATP5B, SDHB, and NDUFB8 were part
of an antibody cocktail purchased from Mitosciences (MitoProﬁles
Total OXPHOS Rodent WB Antibody Cocktail). The Mito ID red dye,
Hoechst stain, and Mdivi-1 were obtained from Enzo life sciences
(Farmingdale, NY, USA). PDGF-BB, palmitoylcarnitine, ADP, pyruvate,
malate, succinate, protease inhibitor cocktail, etomoxir, FCCP, antimy-
cin A and rotenone were obtained from Sigma-Aldrich (St. Louis, MO,
USA). Mouse monoclonal antibody against rat Mfn2 was obtained
from Abcam (ab56889). Mouse monoclonal antibodies against α-
smooth muscle actin, calponin and α-tubulin were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Rabbit monoclonal antibody
against microtubule associated light chain 3 (LC3) was purchased
from Cell Signaling Technologies (Danvers, MA, USA). Antibodies for
PCNA and cyclin D1 were from Santa Cruz.
Cell culture
All animal procedures were performed in compliance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the University of Louis-
ville Institutional Animal Care and Use Committee. Rat aortic
smooth muscle cells were isolated from the aortas of six week-
old, male Sprague-Dawley rats and grown in Dulbecco's Modiﬁed
Eagle's Medium (DMEM; Life Technologies–Invitrogen) supplemen-
ted with 10% (v/v) fetal bovine serum (FBS) and 0.1% streptomycin/
penicillin, as previously described [22,23]. Cells used in experiments
were from between passages 2–7 and were maintained in a
humidiﬁed atmosphere of air and 5% CO2 at 37 1C. At approximately
70% conﬂuency, the VSMCs were serum-starved in DMEM contain-
ing 0.1% FBS for 24 h.
Western blotting
After desired treatments, cells were rinsed twice with sterile
phosphate buffered saline and then lysed in a protein lysis buffer
(pH 7.0) containing 25 mM HEPES, 1 mM EDTA, 1 mM EGTA, 0.1%
SDS, 1% NP-40, and 1protease and phosphatase inhibitors.
Protein concentration in the cell lysates was measured using the
Lowry DC assay (Biorad). For Western blotting, between 0.5 and
25 μg of cell protein (depending on target protein) was applied to
each lane of a 10.5–14% Bis–Tris gel and electroblotted onto a PVDF
membrane. The membrane was then incubated overnight at 4 1C
using appropriate dilutions of primary antibodies. The PVDF
membranes were incubated at room temperature with horse-
radish peroxidase-conjugated secondary antibodies for 1.5 h. After
washing steps, immunoreactive bands were detected with
enhanced chemiluminescent detection reagent (GE Healthcare)
using a Typhoon 9400 Variable Mode Imager (GE Healthcare).
Confocal imaging
Cells plated on glass-bottom dishes were serum-starved for
24 h in 0.1% FBS DMEM. Cells were then stimulated with vehicle or
PDGF and/or Mdivi-1 for the indicated times. For visualization,
mitochondria were stained using the MitoID Red kit (Enzo life
sciences; Farmingdale, NY, USA) following the manufacturer's
protocol. Brieﬂy, MitoID Red and Hoechst stains were diluted in
phenol red–free DMEM supplemented with 25 mmol/L HEPES (pH
7.4) and then added to cells for 10 min. For imaging, cells were
visualized using a Nikon TE-2000E2 microscope interfaced with
a Nikon A1 confocal system and images were acquired using a
60objective lens [24].
Measurement of cellular energetics using the XF24 extracellular ﬂux
analyzer
Cellular energetics was measured in intact VSMCs using a Sea-
horse Bioscience XF24 extracellular ﬂux analyzer as described pre-
viously [18,25], with the following modiﬁcations. Fifty-thousand cells
were seeded in 10 wells of a 24-well XF plate (control group), while
25,000 cells were seeded in the remaining 10 wells (PDGF-treated
group); 4 wells were left unseeded for use as temperature control
wells. This cell seeding density was chosen based on the expected
doubling times of cells treated without or with PDGF [22]. Cells were
then serum-starved in 0.1% FBS DMEM for 24 h and subsequently
stimulated with 20 ng/ml PDGF for 48 h. After PDGF stimulation, the
medium was replaced with DMEM containing 100 mM BSA-palmi-
tate, 5 mM D-glucose, and 100 mM L-carnitine. No L-glutamine or
pyruvate was included in the medium. After equilibration in the
medium for 1 h, baseline oxygen consumption rates (OCRs) of the
cells were recorded. Etomoxir (100 μM) was then injected and
changes in the OCR were recorded. Following these measurements,
FCCP (1 μM), and antimycin A and rotenone (10 μM and 1 μM,
respectively) were sequentially injected, with OCR measurements
recorded after each injection. Data were normalized to total protein
in each well. For normalization, cells were lysed in the 24-well XF
plates using 20 μl/well of protein lysis buffer. Protein concentration
was then measured using the Lowry DC assay kit (Biorad).
For measuring electron transport chain activity, the mediumwas
changed to MAS medium (220 mMmannitol, 70 mM sucrose, 5 mM
MOPS, and 4% fatty acid-free BSA, pH 7.2), and cells were permea-
bilized during the XF assay protocol via injection of the following
from port A: 25 μg/ml saponin in MAS medium, essentially as
described previously [26,27]. Port A also contained substrates to
support Complex I-mediated respiration (5 mM pyruvate, 2.5 mM
malate, and 1 mM ADP) or Complex II-mediated respiration (10 mM
succinate, 1 μM rotenone, and 1 mM ADP). In addition, synthetic
substrates such as duroquinol and TMPDþascorbate were used as
described before [28]. Palmitate oxidation was similarly measured
in permeabilized cells by including palmitoylcarnitine (50 μM) and
malate (0.5 mM) and ADP (1 mM). After measurement of State
3 rates, oligomycin (1 μg/ml) was administered and State 4ο rates
J.K. Salabei, B.G. Hill / Redox Biology 1 (2013) 542–551 543
were measured. Finally, antimycin A (10 μM)7rotenone (1 μM)
was injected to inhibit all consumption of oxygen by mitochondria.
Cell proliferation assays
After serum starvation (24 h), VSMCs were treated for the indicated
durations. For cell harvest, cells were rinsed twice with PBS and then
trypsinized with a 0.25% trypsin solution (Gibco) for 3 min at 37 1C.
Cells were then re-suspended in DMEM containing 10% FBS and cell
numbers were determined using a C6 Accuri ﬂow cytometer.
Statistical analysis
Data are mean7SEM. Experimental groups were compared
using one-way ANOVA, followed by Bonferroni post-tests. Unpaired
Student's t-test was used for direct comparisons. A p-value o0.05
was considered signiﬁcant.
Results
PDGF promotes mitochondrial fragmentation
We ﬁrst assessed how treatment of contractile smooth muscle
cells with PDGF affects the mitochondrial network. For this, VSMCs
were serum-starved for 24 h followed by treatment with PDGF or
vehicle. As shown in Fig. 1A and B, 93% of the cells treated with
vehicle alone harbored vermiform, ﬁlamentous mitochondria.
Exposure of the cells to PDGF, however, led to a remarkable loss
of this mitochondrial network, with nearly all of the cells acquiring
a fragmented (globular) mitochondrial structure. This was asso-
ciated with a 50% decrease in the abundance of Mfn2 (Fig. 1C and
Fig. 1. PDGF induces mitochondrial fragmentation in VSMCs. Mitochondria morphology in contractile and synthetic VSMCs: (A) Representative live-cell confocal images of VSMCs
treated with vehicle (–PDGF) or PDGF (20 ng/ml) for 48 h. Data shown are representative of four independent experiments. Blue¼Hoechst, Red¼MitoID red. (Scale bars: left
panels, 50 μm; right panels, 10 μm). (B) Mitochondria lengths were measured using NIS Elements software and scored as follows: Fragmented (globular), mainly small and round
(o2 μm in diameter); and ﬁlamentous, long and higher interconnectivity (4 2 μm in length). The percentage of cells with indicated mitochondrial morphologies was determined
as a percentage of the total number of stained cells counted. (C) Representative Western blots of mitofusin 2 (Mfn2), optic atrophy 1 (Opa1), dynamin-related protein 1 (Drp1),
and mitochondrial ﬁssion 1 protein (Fis1) in control and PDGF-stimulated cells. (D) Quantiﬁcation of C. Results are representative of three independent experiments. npo0.05 vs.
control (vehicle-treated,  ) cells. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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D), with no signiﬁcant changes noted in the abundance of other
regulators of the mitochondrial network, such as Opa1, Drp1, and
Fis1. Because of these remarkable changes in mitochondrial
structure, we then examined the abundance of some of the key
subunits of the oxidative phosphorylation machinery. As shown in
Fig. 2A–D, there were no remarkable changes in NDUFB8, SDHB,
or ATP5A or ATP5B, which are key proteins in Complexes I, II, and
V, respectively. These results suggest that exposure of VSMCs to
PDGF results in remarkable mitochondrial remodeling in the
absence of gross changes in mitochondrial abundance.
Inhibition of mitochondrial ﬁssion prevents VSMC hyperproliferation
Next, we examined how inhibition of mitochondrial ﬁssion
affects PDGF-induced cell responses. Cells co-treated with PDGF
and Mdivi-1, an inhibitor of mitochondrial ﬁssion [29], showed a
largely preserved ﬁlamentous mitochondrial morphology com-
pared with cells treated with PDGF alone (Fig. 3A and B).
In addition, treatment with Mdivi-1 completely prevented VSMC
proliferation induced by PDGF (Fig. 3C) and inhibited induction of
PCNA and cyclin D1 (Fig. 3D–F). However, Mdivi-1 failed to
prevent PDGF-induced degradation of the contractile proteins
α-smooth muscle actin and calponin (Fig. 4A–C), which were
shown previously to be removed via autophagy [22]. In line with
this observation, increases in the abundance of LC3-I and II were
not affected by the presence of Mdivi-1 (Fig. 4A and D). These data
insinuate a causal role of mitochondrial fragmentation in the
hyperproliferative VSMC phenotype, which is independent of
PDGF-induced autophagy and loss of contractile proteins.
PDGF treatment results in a mitochondrial substrate switch
To determine how PDGF affects mitochondrial metabolism,
we developed a substrate selection assay to delineate metabolic
reliance on glucose and fatty acids. For this, the cell medium
was changed to DMEM containing only glucose, palmitate, and
L-carnitine. After three baseline OCR measurements, etomoxir was
injected. The decrease in basal OCR and the non-mitochondrial
rates of OCR were then used to determine the basal bioenergetic
reliance on fatty acid, versus glucose, oxidation (Fig. 5A). This assay
was then used to interrogate substrate selectivity in contractile and
synthetic VSMCs. As shown in Fig. 5B–D, 85% of the OCR in intact
contractile VSMCs was associated with glucose oxidation, whereas
15% was related with the oxidation of fat. Treatment of the cells
with PDGF-BB for 48 h resulted in a 2-fold increase in apparent fat
oxidation and a concomitant diminishment in glucose oxidation.
The FCCP-stimulated rate of oxygen consumption was not changed
in PDGF-treated cells compared with control cells; however, as
shown in the OCR traces (Fig. 5B), PDGF-treated cells exposed to
etomoxir showed a lower maximal OCR (Fig. 5B). To determine if
inhibiting mitochondrial fragmentation affects substrate selectivity,
VSMCs were treated with vehicle, Mdivi-1, PDGF or PDGFþMdivi-1,
and substrate selectivity of the cells was assessed after 48 h. As
shown in Fig. 5E and F, treatment with Mdivi-1 completely
prevented PDGF-induced increases in fatty acid oxidation.
PDGF treatment does not directly affect mitochondrial electron
transport chain or substrate utilization capacity
To determine if conversion to the synthetic phenotype affected
the ability of mitochondria to respire directly, we assessed State
3 and State 4ο mitochondrial respiration in permeabilized cells.
For this, cells were permeabilized with saponin, allowing for the
controlled delivery of substrates to the mitochondrion (Fig. 6A).
Using this assay, we ﬁrst tested whether the synthetic VSMC
phenotype has an increased capacity to utilize fatty acids. The cell
medium was changed to MAS medium and three baseline oxygen
consumption rates were measured. A mixture of saponin, palmi-
toylcarnitine, and ADP was then injected from port A, and OCRs
Fig. 2. Protein abundance of critical electron transport chain subunits is not affected by PDGF treatment. Immunoblots of subunits of electron transport chain complexes:
(A) After serum-starvation for 24 h, VSMCs were treated with PDGF (20 ng/ml) for up to 48 h. The abundance of ATP synthase, Hþ transporting, mitochondrial F1 complex,
alpha subunit 1 (ATP5A1); succinate dehydrogenase subunit B (SDHB), NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8 (NDUFB8); and ATP synthase, Hþ
transporting, mitochondrial F1 complex, beta polypeptide (ATP5B) were measured by Western blotting. The respective complexes that comprise each subunit are shown to
the left of each representative immunoblot. (B–D) Quantiﬁcation of immunoblots shown in panel A. Results are representative of three independent experiments.
J.K. Salabei, B.G. Hill / Redox Biology 1 (2013) 542–551 545
were measured. Oligomycin and antimycin A/rotenone mix were
then injected sequentially with two OCR measurements recorded
after each injection (Fig. 6B). As shown in Fig. 6C,D, the State 3 and
State 4o values were not signiﬁcantly different between control
(contractile) and PDGF-treated (synthetic) VSMCs. To determine if
Complex I-mediated respiration was different between the groups
State 3 and State 4ο respiration rates were measured in the
presence of pyruvate and malate (Fig. 6E). As shown in Fig. 6F,G,
there was no difference in pyruvate-supported respiration
between the groups. Succinate-supported respiration was not
different between the cell phenotypes either (Fig. 6H–J). Similarly,
we did not ﬁnd changes in duroquinol- or TMPDþascorbate-
supported respiration in the PDGF-treated cells, suggesting that
synthetic cells do not have any difference in mitochondrial
capacity to support electron ﬂow through Complexes III and IV
(data not shown).
Discussion
The present ﬁndings demonstrate a novel dichotomy in the
acquisition of the synthetic VSMC phenotype. PDGF-induced
conversion of VSMCs into the synthetic phenotype was accom-
panied by mitochondrial fragmentation, decreased abundance of
Mfn2, a decrease in apparent glucose oxidation and a concomitant
increase in fatty acid oxidation. Inhibition of mitochondrial frag-
mentation with Mdivi-1 did not prevent PDGF-induced activation
of autophagy or loss of contractive elements, but it did prevent
Fig. 3. Inhibition of mitochondrial ﬁssion prevents PDGF-induced VSMC hyperproliferation. (A) Representative confocal images of VSMC treated with PDGF (20 ng/ml) for
24 h in the absence or presence of Mdivi-1 (10 μm). Blue¼Hoechst nuclear stain; Red¼mitoID red. (Scale bars: left panels, 50 μm; right panels, 10 μm) (B) Quantiﬁcation of
mitochondrial structures shown in panel A: Mitochondria lengths were measured using NIS Elements software and scored as follows: Fragmented (globular;o2 μm in
diameter); intermediate (2–4 μm in length); and ﬁlamentous (44 μm in length). The percentage of cells with the indicated mitochondrial morphologies was determined as a
percentage of the total number of stained cells counted. (n¼3 per treatment group, npo0.05 vs. PDGF-treated cells not exposed to Mdivi-1). (C) Equal numbers of VSMCs
were seeded. Following serum-starvation, the cells were treated without or with PDGF (20 ng/ml) in the absence or presence of Mdivi-1 (10 μm) for 48 h. After
trypsinization, cells were counted using an Accuri ﬂow cytometer. n¼3 (experiments) per group, nnpo0.01 vs. untreated cells, npo0.05 vs. PDGF-treated cells. (D) Western
blots showing the relative abundances of PCNA and cyclin D1 in cells treated for up to 24 h with PDGF in the absence and presence of Mdivi-1. (E,F) Quantiﬁcation of the blots
from panel D (n¼3 per treatment group, nnpo0.01 vs. untreated, control cells). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
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PDGF-induced cell proliferation and the disposition to oxidize fatty
acids. Thus, the hyperproliferative responses caused by PDGF
appear to be due, in part, to its effects on mitochondrial morphol-
ogy and bioenergetic function, which is discrete from the loss of
contractile elements that occurs with conversion to the synthetic
VSMC phenotype. These studies are consistent with previous
studies showing a role of mitochondrial ﬁssion in VSMC hyper-
proliferation. For example, the hyperproliferation of pulmonary
artery smooth muscle cells has been associated with a fragmented
mitochondrial phenotype [20], and inhibition of Drp-1-mediated
mitochondrial ﬁssion with Mdivi-1 prevented not only cell pro-
liferation, but cobalt-induced pulmonary artery hypertension
in vivo as well [19]. These results are in harmony also with
previous studies showing that overexpression of Mfn2 inhibits
VSMC proliferation [30].
The ﬁndings of this study contribute to the understanding of
how mitochondrial structure regulates VSMC metabolism and
hyperproliferative responses. Using a PDGF-induced model of the
synthetic VSMC phenotype [7,18,22], we demonstrate that the
attainment of the synthetic phenotype is associated with remark-
able changes in mitochondrial morphology. With conversion to
the synthetic phenotype, VSMC mitochondria assume a fragmen-
ted (or globular) phenotype. The synthetic cells demonstrate a
greater capacity to oxidize fatty acids and a decreased propensity
to utilize glucose. As a limitation, it should be noted that the
conclusions drawn from intact cell studies were based on the
inhibition of OCR when cells were exposed to etomoxir, an
inhibitor of carnitine palmitoyl transferase (CPT) [31]. Hence, off-
target effects of etomoxir, which may change with cell phenotype,
cannot be ruled out. Nevertheless, it would appear that the
preference for lipid oxidation was increased in synthetic cells.
These studies also facilitated the use of permeabilized cells to
examine metabolic changes intrinsic to the mitochondrion. VSMCs
permeabilized with saponin showed no differences in pyruvate- or
succinate-supported respiration between treatment groups, indicating
that pyruvate and succinate uptake and oxidation in mitochondria is
unaffected by conversion to the synthetic phenotype. Similarly,
palmitoylcarnitine- and glutamine-supported respiration were not
different between contractile and synthetic cells, and PDGF treatment
had no effect on Complex III and IV activities, as indicated by identical
rates in State 3 respiration compared with contractile cells.
Although it is unclear how bioenergetic reprogramming may affect
the hyperproliferative VSMC response, it could be that VSMCs max-
imize their ability to generate energy by increasing mitochondrial β-
oxidation. Lipid oxidation provides more ATP than does oxidation of
carbohydrates (per molecule), although it does diminish energy
efﬁciency [32]. While fatty acid oxidation is known to result in the
generation of FADH2 (which is also generated by succinate dehydro-
genase and similarly transfers electrons to ubiquinone), it generates
NADH as well, which transfers electrons to more thermodynamically
efﬁcient reactions commencing at Complex I [33]. Nevertheless,
smooth muscle cells, both in vivo and ex vivo, would be thought to
have adequate levels of oxygen and thus could afford a lower P:O
stoichiometry. Based on our results, we speculate that metabolism is
restructured in synthetic cells to support the maximum production of
ATP, which is utilized for cell proliferation. It is also possible that
glucose or its metabolites may be diverted into pathways that support
the biosynthesis of phospholipids and DNA, an abundant supply of
which are required in rapidly dividing cells. This would suggest that
increases in fatty acid oxidation could be a consequence of decreased
pyruvate availability. That fatty acid oxidation is not different between
permeabilized synthetic and contractile cells would appear to support
this hypothesis. It is also possible that increased reliance of synthetic
VSMCs on mitochondrial β-oxidation is due to altered allosteric
regulation of β-oxidation enzymes [34].
Perhaps most remarkable is the dichotomous nature of the
conversion to the synthetic cell phenotype. Our previous studies
show that PDGF activates autophagy, which is required for removal
of contractile myoﬁlaments such as α-smooth muscle cell actin
and calponin [22]. Such a conversion is associated with a higher rate
Fig. 4. Inhibition of mitochondrial fragmentation does not affect PDGF-induced changes in autophagy and loss of contractile proteins. Abundance of contractile proteins and
LC3: (A) Representative immunoblot of α-smooth muscle actin (Sm-α-actin), calponin, and microtubule-associated light chain 3 (LC3): VSMCs were serum-starved for 24 h
and then treated with PDGF (20 ng/ml)7Mdivi-1 (10 μM) for 48 h. (B–D) Quantiﬁcation of immunoblots in panel A (n¼3 per group, npo0.05 vs. untreated cells).
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of cell proliferation [7]. The results of this study suggest that the
de-differentiation process occurs via two separate processes, i.e.,
proliferative responses driven by coupled transcriptional and bioe-
nergetic processes, and loss of contractile proteins largely mediated
by autophagy and downregulation of myoﬁlament genes. Interest-
ingly, inhibition of ﬁssion with Mdivi-1 prevented PDGF-induced
upregulation of the cell cycle proteins PCNA and cyclin D1 as well.
This could support the hypothesis that mitochondrial structure and
activity regulate the transcriptional machinery associated with
proliferation.
Collectively, these studies provide novel insights into the role of
mitochondria in PDGF-induced proliferation. Mitochondrial morphol-
ogy appears to be a critical determinant of substrate usage and cell
proliferation. Furthermore, when combined with our previous studies
[22,35], these studies suggest a newmodel of VSMC de-differentiation
in which removal of contractile elements occurs in parallel, but not in
series, with the coordinated bioenergetic and transcriptional changes
that support proliferation (Fig. 7). Compounds that inhibit mitochon-
drial ﬁssion could be promising candidates for preventing diseases
associated with aberrant VSMC hyperproliferation.
Fig. 5. PDGF-mediated increases in mitochondrial fragmentation promote fatty acid oxidation in VSMCs. Measurements of glucose oxidation (GO) and fatty acid oxidation
(FAO) in VSMCs using extracellular ﬂux analysis: (A) Diagrammatic example of metabolic reliance assay: After three baseline measurements, etomoxir (ETO; 100 μm) is
injected. The change in OCR is then recorded, and FCCP (1 μm) and antimycin A (AA; 10 μm) is injected to establish maximal and non-mitochondrial rates of oxygen
consumption, respectively. The equations below the diagram are used to calculate the percent reliance on fatty acid oxidation and glucose oxidation. (B) The assay illustrated
in panel A was used to measure fuel selection in contractile and synthetic cells. VSMCs were treated with vehicle or PDGF (20 ng/ml) for 48 h prior to the assay. (C and D) The
%FAO and %GO were calculated based upon the equations shown in Panel A. (E) VSMCs were treated without or with PDGF for 48 h in the absence or presence of Mdivi-1
(10 μM). These cells were then subjected to the metabolic reliance assay shown in panel A. (F) The %FAO was calculated from data in panel E. Data shown represent three
independent experiments; npo0.05 vs. vehicle-treated control cells, npo 0.05 vs. cells treated with PDGF alone.
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Fig. 6. Permeabilized cell assays in contractile and synthetic VSMCs. OCR traces and indices of mitochondrial respiration in permeabilized cells. VSMCs were treated with vehicle or
PDGF (20 ng/ml) for 48 h followed by permeabilized cell assays. (A) Illustration demonstrating the permeabilized cell, extracellular ﬂux assay: Cell medium is changed to MAS buffer.
After three baseline measurements, saponin (25 μg/ml), mitochondrial substrates, and ADP (1 mM) are injected. Following two more OCR recordings, oligomycin (Oligo, 1 μg/ml) is
injected and two measurements are recorded. Then, antimycin A and rotenone (AA/Rot, 10 and 1 μM, respectively) are co-injected and two more OCR measurements are recorded.
From this assay, the State 3 and State 4ο rates of oxygen consumption are measured. After normalization to total protein, the equations shown to the right are used for calculations. (B)
OCR traces showing palmitoylcarnitine-supported respiration in VSMCs: after three baseline measurements, saponinwas co-injected with ADP and palmitoylcarnitine (50 μm) and the
assay shown in panel Awas completed. (C,D) Quantiﬁcation of State 3 and State 4ο OCRs from panel B. (E) Complex I-mediated respiration: after three baseline measurements, saponin
was co-injected with ADP and pyruvateþmalate (pyr/mal; 5/2.5 mM) and the assay shown in panel A was completed. (F,G) Quantiﬁcation of State 3 and State 4ο OCRs from panel E.
(H) Complex II-mediated respiration: after three baseline measurements, saponin was co-injected with ADP and succinateþrotenone (Succ, 10 mM; Rot, 1 μM). (I,J) Quantiﬁcation of
State 3 and State 4ο OCRs from panel H. Results represent 3–4 independent experiments.
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